Speaker
Description
Successful bone regeneration in clinical research still remains a great challenge due to the complex morphology and the recent advances aim to enhance the rate of bone healing using biofabrication strategies such as 3D bioprinting loaded with growth factors. 3D bioprinting has tremendously boosted the transition from conventional regenerative procedures to customized patient-specific deliverables. Despite the enormous growth of this technology, various factors such as the development and validation of an appropriate biomaterial component of bioinks for a particular tissue, cell sourcing, cell compatibility issues with bioinks, risks associated with unwanted differentiation of loaded cells, etc, have limited the applications in humans. Further, such approaches are expensive, and involves complex regulatory procedures thereby limiting their translation to clinics. Therefore, in the present study, we have incorporated injectable platelet-rich fibrin (iPRF) in the commercially available Cellink bone ink as an alternative to the use of recombinant growth factors and cellular therapy. iPRF is a rich source of autologous growth factors and stem cells and has a significant potential in bone regeneration. We investigated the efficacy of the iPRF incorporated 3D printed scaffolds in the cranial defect models of rabbits. The in-vivo preclinical experiments confirmed the accelerated bone healing with iPRF scaffolds as compared to non-iPRF scaffolds. This disruptive approach may offer the opportunity for tailoring biomaterial inks with a patient's autologous growth factors for 3D printing of bone scaffolds in the operation theatre and subsequent implantation at the defect site as a part of a single stage surgical procedure. This can prove to be a more effective treatment strategy for bone disorders and can help in minimizing the patient recovery time.
96086740959